LBT Innovations Limited

The Automated Plate Assessment System for Antimicrobial Resistance (APAS®-AMR) uses LBT Innovations ground-breaking AI image analysis platform to accurately read and interpret antibiotic susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR).

In 2019, the World Health Organisation identified AMR as one of the top 10 health threats globally. In the United States over 2.8 million antimicrobial resistant infections occur each year causing more than 35,000 deaths.

Clinical laboratories play an important role in antimicrobial stewardship by providing clinicians with essential data to inform treatment for their patients. Millions of ASTs are performed around the world each day by trained microbiologists to direct the appropriate antimicrobial treatment for patients. These tests are time consuming and rely on a series of accurate manual measurements to be taken that are prone to error (shown to be up to 14%).

This project promises to deliver a unique solution by using advanced digital imaging and artificial intelligent image analysis techniques to automatically read AST disc diffusion plates. The APAS®-AMR technology will be deployed using LBT Innovations' FDA cleared APAS® instrument to provide high volume and rapid plate reading for laboratories ensuring accurate and timely reporting of AMR information to clinicians.

BTB Round: Two

State: South Australia


  • MTPConnect Grant: $859,107
  • Industry Contribution: $952,104

Duration: September 2020 – June 2022

Visit LBT Innovations to learn more  |  LinkedIn: LBT Innovations  |  YouTube: LBT Innovations

Contact: Jack Brown

Podcast: LBT Innovations’ Technology Aims to Speed Up Detection of Antimicrobial Resistance (22 November 2021)